These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16318423)

  • 21. The impact of antigen density and antibody affinity on antibody-dependent cellular cytotoxicity: relevance for immunotherapy of carcinomas.
    Velders MP; van Rhijn CM; Oskam E; Fleuren GJ; Warnaar SO; Litvinov SV
    Br J Cancer; 1998 Aug; 78(4):478-83. PubMed ID: 9716030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bispecific antibodies and diabodies for cancer immunotherapy.
    Elsässer-Beile U; Bühler P
    Immunotherapy; 2012 May; 4(5):459-60. PubMed ID: 22642325
    [No Abstract]   [Full Text] [Related]  

  • 23. Bispecific Antibody Armed T Cells to Target Cancer Cells.
    Thakur A; Lum LG; Mittal S
    Methods Mol Biol; 2018; 1722():117-126. PubMed ID: 29264802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alternative molecular formats and therapeutic applications for bispecific antibodies.
    Spiess C; Zhai Q; Carter PJ
    Mol Immunol; 2015 Oct; 67(2 Pt A):95-106. PubMed ID: 25637431
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activated T cells armed with bispecific antibodies kill tumor targets.
    Bhutani D; Lum LG
    Curr Opin Hematol; 2015 Nov; 22(6):476-83. PubMed ID: 26457960
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytokines affect resistance of human renal tumour cells to complement-mediated injury.
    Blok VT; Gelderman KA; Tijsma OH; Daha MR; Gorter A
    Scand J Immunol; 2003 Jun; 57(6):591-9. PubMed ID: 12791098
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant bispecific antibodies for cellular cancer immunotherapy.
    Müller D; Kontermann RE
    Curr Opin Mol Ther; 2007 Aug; 9(4):319-26. PubMed ID: 17694444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytotoxic lymphocytes: redirecting the cell-mediated immune response for the therapy of cancer.
    Kershaw MH; Trapani JA; Smyth MJ
    Ther Immunol; 1995 Jun; 2(3):173-81. PubMed ID: 8885135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhancement of the complement activating capacity of 17-1A mAb to overcome the effect of membrane-bound complement regulatory proteins on colorectal carcinoma.
    Gelderman KA; Kuppen PJ; Bruin W; Fleuren GJ; Gorter A
    Eur J Immunol; 2002 Jan; 32(1):128-35. PubMed ID: 11754353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy of human tumors with T-cell-activating bispecific antibodies: stimulation of cytotoxic pathways in vivo.
    Bauer S; Renner C; Juwana JP; Held G; Ohnesorge S; Gerlach K; Pfreundschuh M
    Cancer Res; 1999 Apr; 59(8):1961-5. PubMed ID: 10213507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection.
    Zhukovsky EA; Morse RJ; Maus MV
    Curr Opin Immunol; 2016 Jun; 40():24-35. PubMed ID: 26963133
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bispecific antibodies for cancer therapy.
    Chames P; Baty D
    Curr Opin Drug Discov Devel; 2009 Mar; 12(2):276-83. PubMed ID: 19333873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies.
    Hoseini SS; Cheung NV
    Cancer Lett; 2017 Jul; 399():44-52. PubMed ID: 28428075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bispecific antibodies for cancer therapy: the light at the end of the tunnel?
    Chames P; Baty D
    MAbs; 2009; 1(6):539-47. PubMed ID: 20073127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activated T-cell and bispecific antibody immunotherapy for high-risk breast cancer. Bench to bedside.
    Lum LG; Sen M
    Acta Haematol; 2001; 105(3):130-6. PubMed ID: 11463985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo.
    Hombach A; Jung W; Pohl C; Renner C; Sahin U; Schmits R; Wolf J; Kapp U; Diehl V; Pfreundschuh M
    Int J Cancer; 1993 Nov; 55(5):830-6. PubMed ID: 8244580
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer Immunotherapy: The Dawn of Antibody Cocktails.
    Marrocco I; Romaniello D; Yarden Y
    Methods Mol Biol; 2019; 1904():11-51. PubMed ID: 30539465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo activation and expansion of T cells by a bi-specific antibody abolishes metastasis formation of human melanoma cells in SCID mice.
    Riedle S; Rösel M; Zöller M
    Int J Cancer; 1998 Mar; 75(6):908-18. PubMed ID: 9506537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beta-glucan enhanced killing of renal cell carcinoma micrometastases by monoclonal antibody G250 directed complement activation.
    Sier CF; Gelderman KA; Prins FA; Gorter A
    Int J Cancer; 2004 May; 109(6):900-8. PubMed ID: 15027124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.